Nicola Wealth Management LTD. Lowers Position in IDEXX Laboratories, Inc. $IDXX

Posted by Brian Himes on May 25th, 2026

Nicola Wealth Management LTD. cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 21.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,800 shares of the company’s stock after selling 4,000 shares during the quarter. Nicola Wealth Management LTD.’s holdings in IDEXX Laboratories were worth $10,013,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the third quarter worth approximately $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth approximately $29,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth approximately $30,000. Greykasell Wealth Strategies Inc. purchased a new stake in shares of IDEXX Laboratories in the third quarter worth approximately $35,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories in the third quarter worth approximately $36,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. UBS Group reduced their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. BTIG Research reduced their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Barclays reduced their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $751.00.

Check Out Our Latest Report on IDEXX Laboratories

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 2,693 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the transaction, the executive vice president directly owned 19,899 shares of the company’s stock, valued at approximately $13,163,984.46. This represents a 11.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 27,777 shares of company stock valued at $18,235,113. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $559.37 on Monday. The stock has a fifty day simple moving average of $566.51 and a two-hundred day simple moving average of $642.13. IDEXX Laboratories, Inc. has a 1-year low of $496.61 and a 1-year high of $769.98. The firm has a market cap of $44.12 billion, a price-to-earnings ratio of 41.19, a price-to-earnings-growth ratio of 3.25 and a beta of 1.58. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the company earned $2.91 earnings per share. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.